Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respi... Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.6 | 5.49253731343 | 83.75 | 88.786 | 83.17 | 2813 | 84.66635071 | CS |
| 4 | -0.2 | -0.225861095426 | 88.55 | 89.53 | 80.742 | 9787 | 83.79516238 | CS |
| 12 | -7.6 | -7.92079207921 | 95.95 | 96.41 | 80.742 | 6182 | 87.24299174 | CS |
| 26 | -9.938 | -10.1111020674 | 98.288 | 98.288 | 80.742 | 22708 | 94.49945041 | CS |
| 52 | -10.354 | -10.4899497487 | 98.704 | 106.34 | 80.742 | 30671 | 95.08352452 | CS |
| 156 | -17.884 | -16.8345350829 | 106.234 | 122.028 | 80.742 | 21639 | 97.05663909 | CS |
| 260 | -17.94 | -16.8783516794 | 106.29 | 122.028 | 73.31 | 25314 | 93.84478491 | CS |
bigtalan
5分前
COminer
8分前
getsome140backagain
11分前
Taleb Spinoza
12分前
tootalljones
13分前
vV NoXious Vv
15分前
ProfitScout
15分前
investingnotgambling
17分前
fuagf
23分前
gdl
24分前
bear777
30分前
SeaBlue
45分前
choo choo trader
45分前
cojoboy
45分前
mick
45分前
SeaBlue
46分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。